Immupharma PLC Lupuzor's Founder Dr Slyviane Muller Awarded Medal
June 25 2015 - 2:00AM
RNS Non-Regulatory
TIDMIMM
Immupharma PLC
25 June 2015
ImmuPharma PLC
25 JUNE 2015
Lupuzor's Founder, Dr Slyviane Muller - Awarded Medal of
Innovation from CNRS
for Lupuzor(TM)
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company is delighted to
announce that Dr Sylviane Muller the key inventor of Lupuzor(TM)
and Research Director at Centre National de la Recherche
Scientifique ("CNRS"), has received "The CNRS Medal of Innovation"
for her discoveries made on the mechanism of action of Lupuzor(TM)
and its applications to other autoimmune diseases.
The CNRS Medal of Innovation, created in 2011, rewards
outstanding scientific research with innovative applications in the
technological, therapeutical and societal fields, thus promoting
French scientific research. Every year, a jury hands out up to five
medals to researchers and engineers, either from CNRS or within
other research organizations, universities and higher-education
institutions, or to industrial partners involved in research
initiatives.
Lupuzor(TM) (also known as Rigerimod, IPP-201101 and P140), is
ImmuPharma's lead compound for the treatment of Lupus, (Systemic
Lupus Erythematosus or "SLE"), a chronic, potentially
life-threatening autoimmune disease. Lupuzor(TM) has been granted
Fast Track status by the US FDA and approved to start Phase III
trials under a Special Protocol Assessment (SPA) due to its strong
safety and efficacy profile. ImmuPharma is now working with
Simbec-Orion Group Limited a leading international contract
research organisation for the execution of ImmuPharma's Pivotal
Phase III clinical study of Lupuzor(TM).
This award for Dr Muller follows on from former recognition of
her works in the field of Lupus and other autoimmune diseases where
she received the CNRS silver medal in 2009 and was awarded
Chevalier de la Légion d'Honneur by President Sarkozy in 2010. A
very large part of her discoveries in the Lupuzor field were
financially supported by CNRS, Robert Zimmer privately and later by
ImmuPharma. Sylviane is also one of the first co-founders of the
precursor of ImmuPharma just after it was founded by Robert Zimmer
in 2002.
ENDS
For further information please contact:
+ 44 (0) 20 7152
ImmuPharma plc (www.immupharma.org) 4080
Dimitri Dimitriou, Chief Executive
Officer
Dr Robert Zimmer, President
and Chief Scientific Officer
Lisa Baderoon, Head of Investor
Relations (lisa.baderoon@immupharma.com) + 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD
& Broker +44 (0) 20 7886 2500
Hugh Morgan
Fred Walsh
Duncan Monteith
Notes to Editors
ImmuPharma PLC
ImmuPharma is a pharmaceutical company listed since 2006 on AIM
of the London Stock Exchange (LSE:IMM), focusing on developing
novel medicines with high sales potential in specialist markets
with serious unmet need. ImmuPharma has five drug candidates in
development, two platform technologies and a multitude of patents
and IP. ImmuPharma is led by a commercially focused Board and
management team with extensive experience. For more information
please go to: www.immupharma.com
Lupuzor(TM)
Lupuzor(TM) also referred to as rigerimod or P140 is
ImmuPharma's lead compound and a potential treatment for lupus (or
Systemic Lupus Erythematosus), a chronic, potentially
life-threatening auto-immune disease. Lupuzor(TM) has a novel
mechanism of action aimed at modulating the body's immune system so
that it does not attack healthy cells, without causing adverse side
effects. It has the potential to halt the progression of the
disease in a substantial proportion of patients.
Lupuzor(TM) has been granted Fast Track status by the US FDA and
approved to start Phase III under Special Protocol Assessment
(SPA). This SPA was subsequently amended due to its strong safety
and efficacy profile to allow for a reduced number of patients in
the pivotal Phase III trial thereby reducing the projected cost of
development considerably. ImmuPharma is now working with
Simbec-Orion Group Limited a leading international contract
research organisation for the execution of ImmuPharma's Pivotal
Phase III clinical study of Lupuzor(TM).
Commercial Opportunity
Current drugs either have serious side effects or have limited
effectiveness. GSK's Benlysta's approval paves the way for
Lupuzor(TM) (first Lupus drug approved in over 50 years). There are
an estimated 1.5 million patients in US, Europe and Japan. The
target price per patient is estimated to be around $10,000 -$20,000
per year. For more information on Lupuzor(TM) please visit:
(www.lupuzor.com)
Dr. Sylviane Muller, Research Director at CNRS & Co-founder
of ImmuPharma France
Sylviane Muller is a distinguished class research director in
the French Centre National de la Recherche Scientifique (CNRS) and
Professor at the Institute of Advanced Studies of the Strasbourg
University, in charge of the chair Therapeutic immunology. Dr
Muller is deputy director of the CNRS Molecular and cellular
biology Institute (IBMC) in Strasbourg (France), Chair and Director
of the CNRS Unit entitled Immunopathology and therapeutic
chemistry, and Head and coordinator of the Drug discovery Center
for cancer and inflammation Medalis awarded 'Laboratory of
Excellence'. Dr Muller defended a doctoral degree in Molecular
Biology in 1978 and a thesis in Science in 1984 in Strasbourg. Dr
Muller was a post-doctoral fellow at the Max-Planck Institute for
Immunobiology in Freiburg (Germany). Dr Muller is the co-author of
249 publications in peer-reviewed journals and 97 review articles
and chapters. Her scientific activity has led to 30 patents (most
are licenced). Dr Muller is the co-founder of two companies, namely
Neosystem (1986) and ImmuPharma (2002). Dr Muller is a member of
the editorial board of several scientific journals and of
international scientific Societies giving numerous lectures in
Europe and the US, and participating in many international meetings
as an invited speaker. Dr Muller co-organized ten international
congresses in the field of autoimmunity and lupus. In recognition
of her works Dr Muller has received the CNRS Silver Medal 2009 and
the CNRS Innovation Medal 2015. She was awarded Chevalier de la
Légion d'Honneur by President Sarkosy in 2010.
CNRS - Centre National de la Recherche Scientifique
CNRS is Europe's largest fundamental research institution. It
was founded in 1939 and is a government-funded research
organization, under the administrative authority of France's
Ministry of Research and has over 30,000 employees and an annual
budget of over EUR3 billion. The CNRS has received many prestigious
awards and has produced 17 Nobel laureates and 11 Fields Medal
award winners. CNRS was ranked Ndeg1 according to the new "Nature
Index" classification before the Chinese Academia of Sciences, The
Max Plank Institute and the University of Harward (Boston).
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFETRFISFIE
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024
